GB202116743D0 - Treatment - Google Patents

Treatment

Info

Publication number
GB202116743D0
GB202116743D0 GBGB2116743.2A GB202116743A GB202116743D0 GB 202116743 D0 GB202116743 D0 GB 202116743D0 GB 202116743 A GB202116743 A GB 202116743A GB 202116743 D0 GB202116743 D0 GB 202116743D0
Authority
GB
United Kingdom
Prior art keywords
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2116743.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Healx Ltd
Original Assignee
Healx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healx Ltd filed Critical Healx Ltd
Priority to GBGB2116743.2A priority Critical patent/GB202116743D0/en
Publication of GB202116743D0 publication Critical patent/GB202116743D0/en
Priority to AU2022392456A priority patent/AU2022392456A1/en
Priority to PCT/GB2022/052933 priority patent/WO2023089328A1/en
Priority to JP2024527790A priority patent/JP2024540439A/ja
Priority to MX2024006105A priority patent/MX2024006105A/es
Priority to EP22812750.2A priority patent/EP4433054A1/en
Priority to CN202280074138.9A priority patent/CN118215479A/zh
Priority to US18/710,477 priority patent/US20250000852A1/en
Priority to CA3238805A priority patent/CA3238805A1/en
Priority to KR1020247016458A priority patent/KR20240108407A/ko
Priority to IL312885A priority patent/IL312885A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2116743.2A 2021-11-19 2021-11-19 Treatment Ceased GB202116743D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB2116743.2A GB202116743D0 (en) 2021-11-19 2021-11-19 Treatment
IL312885A IL312885A (en) 2021-11-19 2022-11-18 Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma
MX2024006105A MX2024006105A (es) 2021-11-19 2022-11-18 Nitroxolina para su uso en el tratamiento o prevencion de un neurofibroma plexiforme.
PCT/GB2022/052933 WO2023089328A1 (en) 2021-11-19 2022-11-18 Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma
JP2024527790A JP2024540439A (ja) 2021-11-19 2022-11-18 叢状神経線維腫の治療又は予防に使用するためのニトロキソリン
AU2022392456A AU2022392456A1 (en) 2021-11-19 2022-11-18 Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma
EP22812750.2A EP4433054A1 (en) 2021-11-19 2022-11-18 Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma
CN202280074138.9A CN118215479A (zh) 2021-11-19 2022-11-18 用于在丛状神经纤维瘤的治疗或预防中使用的硝羟喹啉
US18/710,477 US20250000852A1 (en) 2021-11-19 2022-11-18 Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma
CA3238805A CA3238805A1 (en) 2021-11-19 2022-11-18 Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma
KR1020247016458A KR20240108407A (ko) 2021-11-19 2022-11-18 총상 신경섬유종의 치료 또는 예방에 사용하기 위한 니트록솔린

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2116743.2A GB202116743D0 (en) 2021-11-19 2021-11-19 Treatment

Publications (1)

Publication Number Publication Date
GB202116743D0 true GB202116743D0 (en) 2022-01-05

Family

ID=79163954

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2116743.2A Ceased GB202116743D0 (en) 2021-11-19 2021-11-19 Treatment

Country Status (11)

Country Link
US (1) US20250000852A1 (https=)
EP (1) EP4433054A1 (https=)
JP (1) JP2024540439A (https=)
KR (1) KR20240108407A (https=)
CN (1) CN118215479A (https=)
AU (1) AU2022392456A1 (https=)
CA (1) CA3238805A1 (https=)
GB (1) GB202116743D0 (https=)
IL (1) IL312885A (https=)
MX (1) MX2024006105A (https=)
WO (1) WO2023089328A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202218460D0 (en) * 2022-12-08 2023-01-25 Healx Ltd Treatment
WO2026022492A1 (en) * 2024-07-26 2026-01-29 Healx Limited Nitroxoline for use in the treatment and/or prevention of pain

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2641471T3 (es) * 2008-10-06 2017-11-10 The Johns Hopkins University Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
GB202108224D0 (en) * 2021-06-09 2021-07-21 Healx Ltd Treatment

Also Published As

Publication number Publication date
AU2022392456A1 (en) 2024-05-23
WO2023089328A1 (en) 2023-05-25
US20250000852A1 (en) 2025-01-02
JP2024540439A (ja) 2024-10-31
CA3238805A1 (en) 2023-05-25
MX2024006105A (es) 2024-05-30
KR20240108407A (ko) 2024-07-09
CN118215479A (zh) 2024-06-18
EP4433054A1 (en) 2024-09-25
IL312885A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
IL312981A (en) care
GB202016058D0 (en) Therapeautic treatment
GB202116743D0 (en) Treatment
GB202108224D0 (en) Treatment
GB202103122D0 (en) Treatment
GB202003722D0 (en) Treatment
GB202018400D0 (en) Treatment
GB202002711D0 (en) Treatment
GB202006236D0 (en) New treatment
GB202114373D0 (en) Treatment
GB202109815D0 (en) Treatment
GB202109812D0 (en) Treatment
GB202104666D0 (en) COVID-19 treatment
GB202104416D0 (en) Treatment reginmens
GB202103957D0 (en) Treatment
GB202102488D0 (en) Treatment
GB202102410D0 (en) Treatment
GB202102373D0 (en) Treatment
GB202102369D0 (en) Treatment
GB202102366D0 (en) Treatment
GB202101897D0 (en) Treatment
GB202101875D0 (en) Treatment
GB202101210D0 (en) Treatment
GB202101211D0 (en) Treatment
GB202101212D0 (en) Treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)